Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trialFrances Humby, Raquel Celis, Hasan Rizvi et al.|The Lancet|2021Cited by 315
Rituximab versus tocilizumab in rheumatoid arthritis: synovial biopsy-based biomarker analysis of the phase 4 R4RA randomized trialFelice Rivellese, Raquel Celis, Anna E. A. Surace et al.|Nature Medicine|2022Cited by 277